[Treatment adherence in the recurrent depressive disorders]

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Psychology

Context:

• Recurrent depressive disorders present chronic challenges to treatment compliance.
• Disease complexity and chronicity act as significant barriers to patient adherence.
• Current guidelines encourage comprehensive patient education on depression and management strategies.

Purpose:

• To explore strategies for improving treatment compliance in patients with recurrent depressive disorders.
• To review the efficacy of long-term pharmacotherapy and mood stabilizers in preventing depressive relapse.
• To highlight the benefits of sustained euthymia for managing chronic depression.

Summary:

• Long-term antidepressant therapy, including tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs), reduces depressive relapse by over 50%.
• Mood stabilizers like valproic acid are effective and safer alternatives to lithium for preventing recurrence.
• Maintaining therapeutic dosages is crucial for sustained efficacy, even after initial acute episode treatment.

Impact:

• Improved treatment compliance leads to reduced depression recurrence and potentially decreased long-term vulnerability.
• Sustained euthymia through pharmacotherapy is a key factor in ensuring patient adherence.
• Evidence supports the long-term benefits of pharmacotherapy over psychotherapy for preventing depressive episodes.